Quick Answer
aTYR PHARMA INC reported Operating Income of -$77.63 million for fiscal year 2025.
aTYR PHARMA INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$77.63M | -14.3% |
| 2024 | -$67.91M | -23.7% |
| 2023 | -$54.92M | -18.3% |
| 2022 | -$46.40M | -36.4% |
| 2021 | -$34.02M | -113.8% |
| 2020 | -$15.91M | +30.8% |
| 2019 | -$22.98M | +30.0% |
| 2018 | -$32.82M | +30.4% |
| 2017 | -$47.15M | +18.6% |
| 2016 | -$57.94M | -21.7% |
| 2015 | -$47.62M | -102.2% |
| 2014 | -$23.55M | -20.5% |
| 2013 | -$19.54M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$26.75M | -47.4% | -31.7% |
| June 30, 2025 | -$20.31M | -17.3% | -28.8% |
| March 31, 2025 | -$15.77M | +5.2% | +13.1% |
| September 30, 2024 | -$18.14M | -43.8% | -4.8% |
| June 30, 2024 | -$17.32M | -27.7% | -4.1% |
| March 31, 2024 | -$16.64M | -30.1% | -31.9% |
| September 30, 2023 | -$12.62M | +6.5% | +7.0% |
| June 30, 2023 | -$13.56M | -7.7% | -6.0% |
- aTYR PHARMA INC showed a decrease of -14.3% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, aTYR PHARMA INC’s operating income has declined by 297.2% (from -$19.54 million to -$77.63 million).
- The most recent figure is from aTYR PHARMA INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: